¿°Áõ¼ºÀåÁúȯ¿¡¼ ´ëÀå¾ÏÀÇ ¾à¹°Àû ¿¹¹æ
Chemoprevention of Colorectal Cancer in Inflammatory Bowel Disease
´ëÇѼÒȱâÇÐȸÁö 2014³â 63±Ç 1È£ p.3 ~ p.10
ÇѽÂÈñ(Han Seung-Hee) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÀÌÁ¾ÈÆ(Lee Jong-Hun) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
The risk of developing colorectal cancer is increased in patients with inflammatory bowel disease. Surveillance colonoscopy has not been shown to prolong survival and rates of interval cancer are reported to be high. Continuing colonic inflammation has been shown to be important in the development of colorectal cancer and therefore anti-inflammatory agents such as the 5-aminosalicylates and immunomodulators have been considered as potential chemopreventive agents. This review focuses on various chemopreventive agents that have been clearly shown to reduce the risk of colorectal adenoma and cancer in the patients with inflammatory bowel disease. (Korean J Gastroenterol 2014;63:3-10)
Å°¿öµå
Chemoprevention, Inflammatory bowel diseases, Colorectal neoplasms
KMID :
0614620140630010003
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)